Sector
PharmaceuticalsOpen
₹13.51Prev. Close
₹12.29Turnover(Lac.)
₹1.08Day's High
₹13.51Day's Low
₹13.5152 Week's High
₹27.152 Week's Low
₹9.25Book Value
₹13.29Face Value
₹10Mkt Cap (₹ Cr.)
6.53P/E
135.1EPS
0.1Divi. Yield
07 Aug 2024
12:00 AM
AGM
Announcement Date: 07 Aug, 2024
27 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
7 Aug 2024
12:00 AM
BookCloser
4 Dec 2023
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 5.46 | 4.06 | 4.06 | 4.06 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1.59 | 1.39 | 1.35 | 1.31 |
Net Worth | 7.05 | 5.45 | 5.41 | 5.37 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 2.37 | 3.07 | 3.05 | 3.01 |
yoy growth (%) | -22.88 | 0.85 | 1.4 | 14.51 |
Raw materials | -1.23 | -1.27 | -1.15 | -1.06 |
As % of sales | 52.08 | 41.48 | 37.97 | 35.31 |
Employee costs | -0.42 | -0.43 | -0.43 | -0.33 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.03 | 0.25 | 0.12 | 0.1 |
Depreciation | -0.05 | -0.05 | -0.05 | -0.04 |
Tax paid | -0.01 | -0.06 | -0.03 | -0.03 |
Working capital | 0.35 | 0.27 | -0.22 | -0.59 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -22.88 | 0.85 | 1.4 | 14.51 |
Op profit growth | -91.96 | 21.96 | 2.83 | 1.79 |
EBIT growth | -53.42 | 23.04 | -4.42 | 6.8 |
Net profit growth | -89.21 | 100.78 | 26.76 | 52.37 |
| Particulars (Rupees in Crores.) | Mar-2021 | Mar-2020 |
|---|---|---|
Gross Sales | 2.37 | 3.08 |
Excise Duty | 0 | 0 |
Net Sales | 2.37 | 3.08 |
Other Operating Income | 0 | 0 |
Other Income | 0.25 | 0.17 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
SANJAY VYANKATESH KULKARNI
Managing Director & CEO
BHARAT BRIJMOHAN SHARMA
Whole-time Director
SRIJNA SHARMA
Independent Director
SACHIN CHANDRAKANT CHAVAN
Independent Director
CHETAN BHIKHUBHAI PATEL
Additional Director
Aman Mukesh Chaudhari.
Additional Director
Munna Baijnath Chaurasia
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Ganga Pharmaceuticals Ltd
Summary
Ganga Pharmaceuticals Ltd was incorporated as a Public Limited Company in Aug.94 and promoted by Brij Mohan Sharma. he Company is engaged in the business of manufacturing & trading in Pharmaceuticals & allied products (Ayurveda).In Apr.95, the company took over Ganga pharmaceuticals, a proprietory concern (owned by the same promoter), which was manufacturing and marketing ayurvedic products since the last two decades. The company which manufactures ayurvedic medicines, started commercial production in Apr.95. In Jul.96, it came out with a public issue to part-finance the expansion programme involving setting up of a new manufacturing unit for the manufacture of ayurvedic medicines at Murbad, Maharashtra.The company which commenced exports in Jan.96, has marketing arrangements with parties located in Saudi Arabia, Dubai, Italy, Romania and Russia to market its products in their respective regions.
Read More
What is the Ganga Pharmaceuticals Ltd share price today?
The Ganga Pharmaceuticals Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹13.51 today.
What is the Market Cap of Ganga Pharmaceuticals Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Ganga Pharmaceuticals Ltd is ₹6.53 Cr. as of 22 Apr ‘25
What is the PE and PB ratio of Ganga Pharmaceuticals Ltd?
The PE and PB ratios of Ganga Pharmaceuticals Ltd is 135.1 and 1.02 as of 22 Apr ‘25
What is the 52 Week High and Low of Ganga Pharmaceuticals Ltd?
The 52-week high/low is the highest and lowest price at which a Ganga Pharmaceuticals Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Ganga Pharmaceuticals Ltd is ₹9.25 and ₹27.1 as of 22 Apr ‘25
What is the CAGR of Ganga Pharmaceuticals Ltd?
Ganga Pharmaceuticals Ltd's CAGR for 5 Years at 11.05%, 3 Years at 9.57%, 1 Year at -45.24%, 6 Month at -9.93%, 3 Month at -1.03% and 1 Month at 32.84%.
What is the shareholding pattern of Ganga Pharmaceuticals Ltd?
The shareholding pattern of Ganga Pharmaceuticals Ltd is as follows:
Promoters - 56.02 %
Institutions - 0.00 %
Public - 43.98 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
